

## South East England General EQA Scheme AGM MINUTES

| Title of Meeting:           | EQA Annual General Meeting      |                  |                                    |
|-----------------------------|---------------------------------|------------------|------------------------------------|
| Venue:                      | Virtual Microsoft Teams Meeting | Time:            | 12:00 PM                           |
| Minute Taker:               | Louise Knowler                  | Date of meeting: | Friday 14 <sup>th</sup> June, 2024 |
| PowerPoint<br>Presentation: | AGM 2023<br>PowerPoint.pptx     |                  |                                    |

| Present           |                  |                        |                      |  |
|-------------------|------------------|------------------------|----------------------|--|
| Dr Nipin Bagla    | Gill Donald      | Helen Dasley           | Louise Knowler       |  |
| Scheme Organiser  | Scheme Manager   | Scheme Quality Manager | Scheme Administrator |  |
| Hayley Williams   | Dr A Elsayed Ali | Dr S Balija            | Dr D Housa           |  |
| Pathology Quality |                  |                        |                      |  |
| Manager           |                  |                        |                      |  |
| Dr A Goel         | Dr I Morrison    | Dr B Boyle             | Dr K Ramesar         |  |
| Dr A Talwar       | Dr M Al-Jafari   | Dr J Tan               | Dr S Al-Sam          |  |
| Dr L Fulford      | Cr N Chandrasiri | Dr N Williams          | Dr A Nayar           |  |
| Dr P Idaewor      | Dr R Thambi      | Dr T Warusavithana     | Dr S Samarathunga    |  |
| Dr S Adamane      | Dr P Mishra      | Dr N Nind              | Dr G Vittay          |  |
| Dr P Yogananda    | Dr B Latifaj     | Dr S Roberts           | Dr T Elazzabi        |  |
| Dr R Stitson      |                  |                        |                      |  |

| Apologies   |                  |             |
|-------------|------------------|-------------|
| Dr Di Palma | Dr Kempalingaiah | Dr M Moonim |

| New Minutes  |        |         |  |
|--|--------|---------|--|
| Minute number and decision   | Action | Date by |  |
| 1. Welcome & introduction of scheme staff  |        |         |  |
| Dr Nipin Bagla (NB) welcomed all participants who joined the teams meeting and introduced the scheme staff. He noted that the meeting was being recorded to allow for minute taking. |        |         |  |
| 2. Scheme report / Costs and Accounts (changes and developments)   |        |         |  |
| Annual report 2023<br>NB reviewed the RC Path annual report with no comments made.   |        |         |  |
| <b>Scheme Activity</b><br>Last year closed at 176, currently 186, (190 pending eligibility checks).<br>NB advised members that the scheme has temporarily closed                     |        |         |  |

 Document title: AGM Minutes Template
 Page 1 of 7

 WARNING: This document is only controlled if viewed electronically from its original location if the hard copy is
 Printed Copy No.

 validated
 Validated by: (signature)

 Approved by: Scheme Manager
 Validated by: (signature)

 Date of issue: June 2024
 Master copy registered on Pathology Qpulse database

| Histopathology EQA Scheme       Revision 2023         registrations for new out of area applicants. Any new applicants are wait listed until further notice.       Image: Costs and Accounts 2023-24         The number of registered participants sits at 186, with an annual subscription fee of £360.00 for UK participants and £300.00 for international participants.       Image: Costs and Accounts 2023-24         NB explained that the scheme was in the process of re-assessing the contribution costs for 25/26.       Image: Costs and Accounts 2023         3. UKAS       Scheme Accreditation         NB informed participants that following the last UKAS visit in September 2023, we successfully retained our accreditation against ISO17043:2010.         We received 0 Findings 8 small recommendations.         • 232525-03-E01434-001         Recommended including objective evidence in auditor training and competency records and to ensure records of training and awareness of the 17043 standards are also included for non-scheme pathology staff.         • 232525-03-E01434-002         It is recommended that internal audits include evidence of staff compliance with procedures as well as conformity with the standard.         • 232525-03-E01434-003         Recommend that management considers documenting the risk assessment for the Omnis response scoring database         • 232525-03-E01434-004 |  |
|---|--|
| listed until further notice.<br>Costs and Accounts 2023-24<br>The number of registered participants sits at 186, with an annual<br>subscription fee of £360.00 for UK participants and £300.00 for<br>international participants.<br>NB explained that the scheme was in the process of re-assessing the<br>contribution costs for 25/26.<br>3. UKAS<br>Scheme Accreditation<br>NB informed participants that following the last UKAS visit in September<br>2023, we successfully retained our accreditation against ISO17043:2010.<br>We received 0 Findings 8 small recommendations.<br>• 232525-03-E01434-001<br>Recommended including objective evidence in auditor training and<br>competency records and to ensure records of training and awareness of<br>the 17043 standards are also included for non-scheme pathology staff.<br>• 232525-03-E01434-002<br>It is recommended that internal audits include evidence of staff<br>compliance with procedures as well as conformity with the standard.<br>• 232525-03-E01434-003<br>Recommend that management considers documenting the risk<br>assessment for the Omnis response scoring database<br>• 232525-03-E01434-004   |  |
| The number of registered participants sits at 186, with an annual subscription fee of £360.00 for UK participants and £300.00 for international participants.         NB explained that the scheme was in the process of re-assessing the contribution costs for 25/26. <b>3. UKAS</b> Scheme Accreditation         NB informed participants that following the last UKAS visit in September 2023, we successfully retained our accreditation against ISO17043:2010. We received 0 Findings 8 small recommendations.         • 232525-03-E01434-001         Recommended including objective evidence in auditor training and competency records and to ensure records of training and awareness of the 17043 standards are also included for non-scheme pathology staff.         • 232525-03-E01434-002         It is recommended that internal audits include evidence of staff compliance with procedures as well as conformity with the standard.         • 232525-03-E01434-003         Recommend that management considers documenting the risk assessment for the Omnis response scoring database         • 232525-03-E01434-004  |  |
| contribution costs for 25/26.         3. UKAS         Scheme Accreditation         NB informed participants that following the last UKAS visit in September         2023, we successfully retained our accreditation against ISO17043:2010.         We received 0 Findings 8 small recommendations.         • 232525-03-E01434-001         Recommended including objective evidence in auditor training and competency records and to ensure records of training and awareness of the 17043 standards are also included for non-scheme pathology staff.         • 232525-03-E01434-002         It is recommended that internal audits include evidence of staff compliance with procedures as well as conformity with the standard.         • 232525-03-E01434-003         Recommend that management considers documenting the risk assessment for the Omnis response scoring database         • 232525-03-E01434-004   |  |
| <ul> <li>Scheme Accreditation NB informed participants that following the last UKAS visit in September 2023, we successfully retained our accreditation against ISO17043:2010. We received 0 Findings 8 small recommendations. <ul> <li>232525-03-E01434-001</li> <li>Recommended including objective evidence in auditor training and competency records and to ensure records of training and awareness of the 17043 standards are also included for non-scheme pathology staff. <ul> <li>232525-03-E01434-002</li> </ul> It is recommended that internal audits include evidence of staff compliance with procedures as well as conformity with the standard. <ul> <li>232525-03-E01434-003</li> </ul> Recommend that management considers documenting the risk assessment for the Omnis response scoring database <ul> <li>232525-03-E01434-004</li> </ul> </li> </ul></li></ul>  |  |
| NB informed participants that following the last UKAS visit in September<br>2023, we successfully retained our accreditation against ISO17043:2010.<br>We received 0 Findings 8 small recommendations.<br>• 232525-03-E01434-001<br>Recommended including objective evidence in auditor training and<br>competency records and to ensure records of training and awareness of<br>the 17043 standards are also included for non-scheme pathology staff.<br>• 232525-03-E01434-002<br>It is recommended that internal audits include evidence of staff<br>compliance with procedures as well as conformity with the standard.<br>• 232525-03-E01434-003<br>Recommend that management considers documenting the risk<br>assessment for the Omnis response scoring database<br>• 232525-03-E01434-004   |  |
| Recommended including objective evidence in auditor training and<br>competency records and to ensure records of training and awareness of<br>the 17043 standards are also included for non-scheme pathology staff.<br>• 232525-03-E01434-002<br>It is recommended that internal audits include evidence of staff<br>compliance with procedures as well as conformity with the standard.<br>• 232525-03-E01434-003<br>Recommend that management considers documenting the risk<br>assessment for the Omnis response scoring database<br>• 232525-03-E01434-004   |  |
| It is recommended that internal audits include evidence of staff<br>compliance with procedures as well as conformity with the standard.<br>• 232525-03-E01434-003<br>Recommend that management considers documenting the risk<br>assessment for the Omnis response scoring database<br>• 232525-03-E01434-004   |  |
| <ul> <li>Recommend that management considers documenting the risk assessment for the Omnis response scoring database</li> <li>232525-03-E01434-004</li> </ul>   |  |
|   |  |
| they apply to printed templates already in use, especially as completion<br>of a checklist can take several months.   |  |
| • 232525-03-E01434-005<br>Recommend providing information to participants on the potential risk of<br>scoring if they supply a result for a case in their exempted categories.  |  |
| • 232525-03-E01434-006<br>Recommend using similar wording for clarity in documentation as to who<br>has responsibility selection of cases.  |  |
| • 232525-03-E01434-007<br>Recommendation to ensure the scheme specifies the minimum resolution<br>for scanned digital images to meet current practice   |  |
| • 232525-03-E01434-008<br>Recommend the scheme considers their policy for storage and retention<br>of Teams case consultation recordings.   |  |
| <ul> <li>Our next surveillance visit with UKAS again the new ISO standard<br/>ISO 17043:2023, taking place in October 2024.</li> </ul>  |  |

 Document title: AGM Minutes Template
 F

 WARNING: This document is only controlled if viewed electronically from its original location if the hard copy is
 F

 validated
 Validated by: (signature)

 Date of issue: June 2022
 Master copy registered on Pathology Qpulse database

Approved by: Scheme Manager Date of issue: June 2022 Validated by: (signature)

| <ul> <li>We are currently working on a gap analysis to allow transition for<br/>re-assessment in 2024.</li> </ul>   |                                 |
|---|---------------------------------|
| 4. 2023-2024 Scheme Discussion  |                                 |
| 4a. Participant Survey Results  |                                 |
| NB noted that the scheme undertook 2 surveys during this circulation.<br>GD explained the surveys undertaken through the year, discussing each<br>survey in detail.                 |                                 |
| Glass slide and Digital Image – 77 people responded   |                                 |
| Glass Slide and<br>Digital Image  |                                 |
| Survey Results on Digital vs. Glass Slides:   |                                 |
| Majority use a combination of digital and glass slides  |                                 |
| Gradual transition towards digital is occurring   |                                 |
| Digital-only usage is increasing  |                                 |
| Preferences and Challenges:   |                                 |
| <ul> <li>Digital images used as backup when glass slides<br/>unavailable</li> </ul>   |                                 |
| <ul> <li>Some organ systems/diagnoses more challenging on<br/>digital (e.g., haematology/lymphoid)</li> </ul>   |                                 |
| Histology generally easier on digital, but opinions vary  |                                 |
| Current Practices:  |                                 |
| <ul> <li>Many review glass slides at work, then use digital at<br/>home</li> </ul>  |                                 |
| <ul> <li>Mix of digital and glass usage, with digital becoming<br/>more common</li> </ul>   |                                 |
| Future Outlook:   |                                 |
| <ul> <li>Expectation of full digitization in 4-5 years for most<br/>departments</li> </ul>  |                                 |
| <ul> <li>Some cases will still require glass slides (e.g.,<br/>cytology, complex lymphoid cases)</li> </ul>   |                                 |
| Technical Considerations:   |                                 |
| 40x magnification chosen for scanning   |                                 |
| <ul> <li>Varying usage of digital images between home and<br/>work</li> </ul>   |                                 |
| Home internet often faster than office connections  |                                 |
| The group discussed that there would be a continued gradual transition to digital pathology, this should ensure that there is access to high-quality home internet for remote work. |                                 |
|   | Page 3 of 7<br>Printed Copy No. |

Master copy registered on Pathology Qpulse database

| South East England General<br>Histopathology EQA Scheme | RWF- EQA-MIN5<br>Revision 2023 | Maidstone and Tunbridge Wells NHS Trust |
|---|--------------------------------|---|
|   |                                |   |

| should be conside         | cloud-based hosting for digital pathology services<br>ered. NB discussed that the scheme is preparing for<br>usage in coming years, while maintaining glass slide<br>ecific cases.   |  |
|---------------------------|--|--|
| Participant ISO           | survey – 18 people responded   |  |
| Participant ISO<br>Survey |  |  |
| Overall, the discuments   | ssion indicates that the scheme is functioning well for<br>, with decisions made to maintain its current structure<br>clusivity for all independently reporting pathologists.  |  |
| Annual Participat         | ion Certificate:   |  |
| •                         | Most participants use the scheme for appraisal purposes, which aligns with its main goal.  |  |
| •                         | The certificate provides adequate information for most users.  |  |
| •                         | Only one participant suggested including additional CPD activity information, but didn't specify what.   |  |
| Participant Eligibi       | ility:   |  |
| •                         | The scheme includes both consultants on the specialist register and other grades doing independent reporting.  |  |
| •                         | Decision: Allow participation for anyone the local department certifies as doing independent reporting.  |  |
| Grouping of Parti         | cipants:   |  |
| •                         | Survey showed mixed responses on whether to separate non-specialist register participants.   |  |
| •                         | Keep all participants in one core group.   |  |
| •                         | GD and NB outlined that being on the specialist<br>register doesn't necessarily indicate better pathology<br>skills and so long as the doctor is reporting<br>independently without supervision, they remain as part<br>of the core group. |  |
| Scheme Structure          | e:   |  |
| •                         | Most participants are satisfied with the current structure.  |  |
| •                         | Maintain the current scheme structure without adding further exemptions.   |  |
| Generalist vs. Sp         | ecialist Nature:   |  |
| •                         | The scheme aims for a generalist consensus, which can sometimes conflict with specialist expertise.  |  |
| •                         | Acknowledgment: In some cases, generalist consensus may be less precise than specialist  |  |

**RWF- EQA-MIN5** Revision 2023

| opinions.<br>Case Mix:  |                              |
|---|------------------------------|
|   |                              |
| <ul> <li>The scheme receives compliments from UKAS peer<br/>assessors on the suitability of its case mix.</li> </ul>  |                              |
| GD and NB thanked participants for their continued support.   |                              |
| 4b. Case availability   |                              |
| Case stock under 10%:   |                              |
| - Digital 1%  |                              |
| - Endocrine 2%  |                              |
| - Respiratory 5%  |                              |
| - Breast 7%   |                              |
| - Educational 8%<br>- Lympho 8%   |                              |
| - Gynae 8%  |                              |
| - Miscellaneous 8%  |                              |
| - GU 9%   |                              |
| GD thanked participants for their contribution to the scheme, noting that<br>any cases are welcomed, with specific focus on those categories that are<br>propositionally low, such as Digital <i>[miscellaneous]</i> , Endocrine<br>Respiratory, Breast, and Educational.   |                              |
| GD noted that in the last year, the scheme received 25 cases, from only 16 participants. Over 50% of participants not fulfilling new case submission.   |                              |
| All new participants now need to submit one new case as part of their entry criteria. This is proving successful – 11 new cases in May 2024.  |                              |
| GD asked to please submit at least one case a year and reminded participants of their obligation to the scheme to ensure its continuation.  |                              |
| 4c. Changes to the scheme   |                              |
| <b>i.</b> New SAP representative for Sussex<br>Following the retirement of Dr Hawley, Dr Zainab AI-Shiekh Ali was<br>nominated as the new SAP representative for Sussex.and attended his<br>first meeting in May 2024.  |                              |
| <b>ii. Collusion Disclaimer tick box_Pilot</b><br>Following discussion at the RCPath G153 meeting, the group agreed the<br>need for a collusion disclaimer sentence to be added to the participant<br>response form template [RWF-CP-EQA-TEM2], including a tick a box to<br>confirm that the answers are their own and not in collusion with<br>colleagues. This has now been implemented. |                              |
| NB noted that several reminders were sent to participants overall going well.   |                              |
| iii. Quoracy_Less chasing emails due to complaint<br>Following user feedback, reminder notifications have been reduced to<br>two messages on the final consultation day. The scheme now sends only  |                              |
|   | age 5 of 7<br>inted Copy No. |
| Approved by: Scheme Manager         Validated by: (signature)           Date of issue: June 2022         Master copy registered on Pathology Qpulse database  |                              |

Approved by: Scheme Manager Date of issue: June 2022 Validated by: (signature)

| two reminder notifications on the final day of consultation, improving the user experience while still ensuring participants are adequately informed of deadlines.  |   |
|---|---|
| While Dr Goel proposed enhancing case consultation participation<br>through real-time polling during case discussion meetings, GD noted that<br>this approach would not be compatible with the scheme's established<br>statistical analysis methodology. The current analytical framework<br>requires standardised data collection procedures that cannot be<br>replicated through polling exercises. |   |
| <b>iv. Implementation of Digital-Only Category</b> A new digital-only category will replace the existing duplicate 10th category, specifically designed to accommodate digital cases and small biopsies requiring single H&E slide assessment.  |   |
| <b>v. EQA Lite Progress Update</b> The pilot phase of EQA Lite is currently underway in Round y, running parallel to standard assessment processes with existing EQA Lite users. A comprehensive pilot (Round z) is scheduled for September 2024, marking the next phase of implementation.   |   |
| <b>vi. New Participant Case Submission Policy</b> To ensure active participation and maintain quality standards, scheme membership now requires all new participants to submit one case as part of their initial registration process.  |   |
| <b>vii. Enhanced Educational Case Discussions</b> To promote knowledge sharing and professional development, case submitters are now invited to present and lead discussions on their educational cases during the respective assessment rounds.  |   |
| <b>viii. Financial Planning Update</b> Membership fees will remain<br>unchanged for the 2024/25 period. A comprehensive review of EQA Lite's<br>impact on operational costs will inform adjusted pricing structures for<br>2025/26.   |   |
| <b>ix. Temporary Membership Restrictions</b> Due to the pending EQA Lite implementation, the scheme has temporarily suspended applications for out-of-area membership requests. Currently, there are 12 applicants on the waiting list, with applications to resume following the successful implementation of EQA Lite.  |   |
| 4d. Possible future changes to the scheme   |   |
| i. EQA Lite evaluation<br>As above  |   |
| ii. ISO 17043:2023<br>Transition plan and gap analysis have been drafted, and implementation<br>of the new standard is under way.   |   |
| <b>iii. Paperless Scheme</b><br>Review of current documents underway. With the introduction of EQA lite<br>in the future, this includes the functionality to send electronic results.   |   |
| Document title: AGM Minutes Template<br>WARNING: This document is only controlled if viewed electronically from its original location if the hard<br>validated  | Page 6 of 7<br>d copy is Printed Copy No. |

Master copy registered on Pathology Qpulse database

RWF- EQA-MIN5 Revision 2023

|                 | 5. Any other business   | ſ   | [        |
|-----------------|---|---|----------|
| <b>a.</b><br>i. | <b>Membership Costs Review</b><br>The cost of slide scanning, server storage and administration has<br>increased in January 2023. The overall increase for scanning two<br>rounds is up by 22.44 % (£147), from £655 to £802 +vat.  |   |          |
|                 | Dr Al-Jafari noted that it would be useful to provide a financial statement showing income against expenses.  | Action: GD  |          |
| ii.             | Anticipated finances for 2024/2025 show a possible deficit.   |   |          |
| iii.            | Remain static 24/25, prices will change for 25/26 following a review of the impact of EQA lite on scheme overheads.   |   |          |
| b.              | <ul> <li>Slide Selection Criteria_Incorrect organ system</li> <li>NB wanted to reinstate this in light of lymphoma category appeals for respiratory case.</li> <li>'Correct Organ system. Cases that have been placed in the incorrect organ system should be rejected for the current circulation and given to the Scheme Administrator for recategorisation in the correct organ system for future selection. (Note: case contributors occasionally state the diagnostic system rather than the tissue type. All slides must be categorised according to their Organ system, not their diagnosis (source).</li> </ul> |   |          |
| c.              | Slido Poll  |   |          |
| Wh              | at type of scheme email reminders are helpful to you?   |   |          |
| Ro              | und deadlines - 100%  |   |          |
| Со              | nsultation deadlines - 92%  |   |          |
| Slic            | de circulation to next trust - 67%  |   |          |
| Mir             | nimum Participation Reminder - 33%  |   |          |
| l do            | on't want reminders - 0 votes   |   |          |
|                 | 6. Date and venue for next meeting  |   |          |
| NB              | e and time of the next virtual meeting to be agreed.<br>and GD thanked participants and scheme staff for their support and<br>d work.   | LK to<br>circulate a<br>date and<br>time for<br>2025. | Jan 2025 |

Page 7 of 7 Printed Copy No.